Latest studies
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging study of Efficacy and Safety of SAR441566 in Adults with Moderate to Severe Plaque Psoriasis
This study is testing a new medicine called SAR441566 for moderate to severe plaque psoriasis. Researchers want to see if it helps improve psoriasis symptoms and if it's safe. It's a key step to understand if this medicine could become a future treatment option.
PsoriasisPortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Single Arm, Open Label Multicentre Extension Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trial
This study looks at how well a medicine called ocrelizumab works and if it's safe for people with multiple sclerosis (MS). It's for patients who have already been in similar studies with the same medicine.
Multiple sclerosis (MS)Portugal - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Comparative Bioavailability of Ruxolitinib 20 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions.
This study looks at how well a new tablet form of a medicine called ruxolitinib is absorbed by the body. It involves healthy adult volunteers who will take the medicine on an empty stomach. The main goal is to make sure the new tablet works the same way as the original medicine.
No medical condition.Portugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized Study of Andexanet Alfa Compared to Usual Care in Patients Receiving a Factor Xa Inhibitor who Require Urgent Surgery or Procedure (ANNEXA-RS)
This study is comparing a new medication called Andexanet Alfa to usual care. It's for patients who are taking blood thinners (like apixaban, rivaroxaban, or edoxaban) and need urgent surgery. The aim is to see if Andexanet Alfa helps stop bleeding during their operation.
Reversal of anticoagulation effect in patients on a FXa inhibitor (apixabanrivaroxabanor edoxaban) who require urgent surgery or procedureand who have a major risk of bleeding.Portugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
I6T-MC-AMBA - A Multicenter, Phase 3, Open-Label Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age with Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine, Mirikizumab (also called Omvoh), for children and teenagers aged 2 to under 18 who have moderate to severe ulcerative colitis. We want to see how well it works and if it's safe to help them feel better.
Moderately to Severely Active Ulcerative ColitisPortugal - Ongoing, recruitingTherapeutic exploratory (Phase II)
(20289) A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors
This study is testing a new medicine, larotrectinib, for adult patients with certain types of cancer that have a specific genetic change called an 'NTRK fusion'. Doctors want to see how well the medicine shrinks these tumours and if it's safe.
Solid tumors harboring NTRK fusionPortugal - Ongoing, recruitingPhase III and phase IV (Integrated)
A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherapy compared with placebo in subjects with moderate-to-severe atopic hand eczema who are candidates for systemic therapy (ADHAND)
This study is looking into a new treatment called tralokinumab for adults with moderate to severe eczema on their hands. It wants to see how well it works and if it's safe compared to a dummy treatment. The goal is to see if the medicine can clear up or significantly improve hand eczema in a few months.
Atopic dermatitis and moderate-to severe atopic hand eczemaPortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SoC), Compared to a SoC Treated Control Arm, in Prevention of Post Abdominal Surgery Incisional Infection.
This study is testing if a treatment called D-PLEX can help prevent infections after tummy surgery. It compares D-PLEX plus usual care to just usual care, to see if it reduces surgical wound infections.
Prevention of post abdominal surgery incisional infection.Portugal - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants with Chronic Rhinosinusitis Without Nasal Polyps – The BiRCh Study
This study is looking into a new tablet called brensocatib for adults with long-term sinus problems that don't involve growths (nasal polyps). It wants to see if this new medicine can help reduce symptoms like stuffy nose and improve how people feel, compared to a dummy pill.
Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)Portugal - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of KER-012 in Combination with Background Therapy in Adult Participants with Pulmonary Arterial Hypertension (TROPOS-Study)
This study is testing a new medicine, cibotercept (also known as KER-012), for adults with pulmonary arterial hypertension (high blood pressure in the lungs). Researchers want to see if it's safe and helps improve lung blood vessel function when added to existing treatments.
Pulmonary Arterial HypertensionPortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE)
This study is testing a new medicine called semaglutide for people with early Alzheimer's disease. Researchers want to see if it can help improve memory and thinking, and how safe it is to use.
Mild cognitive impairment (MCI) or mild dementiaboth of the Alzheimer’s typePortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus)
This study is looking at a new tablet, semaglutide, to see if it can help people with early Alzheimer's disease. Researchers want to know if it's safe and if it can slow down changes in memory and thinking over about two years.
Mild cognitive impairment (MCI) or mild dementiaboth of the Alzheimer’s typePortugal - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of RO7303509 in Patients with Systemic Sclerosis
This study is looking at a new medicine called RO7303509 for people with Systemic Sclerosis. It wants to see if the medicine is safe, how the body handles different doses, and if there are any side effects. This is one of the first studies in humans.
Systemic SclerosisPortugal - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, randomized, double-blind, placebo-controlled, parallel group, proof-of-concept study assessing the efficacy and safety of amlitelimab in adult participants with moderate to severe hidradenitis suppurativa.
This study is testing a new medicine, amlitelimab, for adults with moderate to severe hidradenitis suppurativa (HS). Researchers want to see if it helps improve HS symptoms and is safe, compared to a dummy drug, over 16 weeks.
HidradenitisPortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
This study is for people with advanced stomach or gut cancer that has a specific genetic marker called FGFR2b. It tests a new drug, bemarituzumab, combined with usual treatments (chemotherapy and nivolumab) to see if it works better than usual treatments alone.
Gastric and Gastroesophageal Junction Cancer With FGFR2b OverexpressionPortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression FORTITUDE-101)
This study looks at a new drug, bemarituzumab, for advanced stomach or gullet cancer that hasn't been treated before. It aims to see if adding bemarituzumab to standard chemotherapy helps people live longer and improves their quality of life compared to chemotherapy alone.
Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpressionPortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected squamous cell carcinoma of the head and neck, who are at high-risk for relapse and are ineligible for high-dose cisplatin
This study looks at a new medicine called xevinapant, given with radiotherapy, for people who have had surgery for head and neck cancer. It compares this treatment to radiotherapy with a dummy medicine, to see if xevinapant helps prevent the cancer from coming back.
Resected squamous cell carcinoma of the head and neckPortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients with Hereditary Angioedema Type I or II A Pharmacokinetic Subtrial in Adolescent Patients with Hereditary Angioedema Type I or II Participating in the KVD900-302 Trial
This study looks at how safe a medicine called KVD900 is when used long-term for swelling attacks in people with Hereditary Angioedema (HAE) Type 1 or 2. It also checks how the body handles the medicine in teenagers.
Hereditary Angioedema Type I or IIPortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (Oberon)
This study is looking at a new medicine called Tozorakimab for people with COPD. It aims to see if it can reduce severe flare-ups and if it's safe. Participants will be compared to those taking a dummy medicine.
Chronic Obstructive Pulmonary Disease (COPD)Portugal - Ongoing, recruitingPhase II and Phase III (Integrated)
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)
This study is looking at a new medicine called bexotegrast for idiopathic pulmonary fibrosis (IPF). It aims to see if the medicine can help improve lung function and slow down the disease, and if it's safe to use. Some participants will receive the medicine, and others a dummy pill.
Idiopathic pulmonary fibrosis (IPF)Portugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
This study is testing a new tablet, Aficamten, for people with a heart condition called non-obstructive hypertrophic cardiomyopathy. It compares Aficamten to a dummy pill to see if it improves how people feel and their exercise ability.
SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHYPortugal - Ongoing, recruitingPhase II and Phase III (Integrated)
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH)
This study is looking into a new treatment, AV-101, for Pulmonary Arterial Hypertension (PAH), a condition affecting the lungs and heart. It aims to see if the treatment is safe and effective by comparing it to a dummy medicine.
Pulmonary Arterial Hypertension (PAH)Portugal - Ongoing, recruitingTherapeutic exploratory (Phase II)
A multi-center, randomized, placebo- and active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure
This study is looking into a new medication called XXB750 for people with heart failure. It hopes to see how well it works, what dose is best, and if it's safe compared to a dummy treatment or existing medicines.
Heart FailurePortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Single-arm, Open-label Extension of the Vericiguat VALOR Study in Pediatric Participants with Heart Failure due to Systemic Left Ventricular Systolic Dysfunction (VALOR EXT)
This study looks at a medicine called Vericiguat for children with a type of heart failure. It checks how safe the medicine is and if it causes any unwanted effects. This is a follow-up study for those already taking part.
Heart Failure due to Systemic Left Ventricular Systolic DysfunctionPortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
IMPAHCT-FUL: A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002
This study looks at the long-term safety of a new medicine, AV-101, for people with pulmonary arterial hypertension (PAH). It's for those who have already tried AV-101 in a previous study and aims to learn more about how well it's tolerated over time.
Pulmonary Arterial Hypertension (PAH)Portugal - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Comparative Bioavailability of Lisdexamfetamine Dimesylate 70 mg in Healthy Subjects Under Fasting Conditions
This study is looking at how a 70mg dose of a medicine called lisdexamfetamine dimesylate is absorbed in healthy adults. It's a very early-stage study to understand the medicine better.
No medical condition.Portugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS)
This study is looking at new inhalers for adults with asthma that isn't well-controlled. It aims to see if a new combination inhaler works better than current ones to improve breathing and reduce asthma attacks.
Severe and inadequately controlled asthmaPortugal - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Safety Study to Compare the Gastrointestinal Tolerability of Oral Tegomil Fumarate and Dimethyl Fumarate (Tecfidera®) in Healthy Volunteers.
This study is looking at a new medicine called Tegomil Fumarate. It's compared to an existing medicine, Tecfidera®, to see which is easier on the stomach and gut. This is a very early study in healthy people, not people with a specific illness.
Multiple SclerosisPortugal - AuthorisedHuman Pharmacology (Phase I)- Bioequivalence Study
A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavailability at Steady-State of LY03010 versus XEPLION® in Patients with Schizophrenia
This study is looking at a new version of a medication for schizophrenia. It compares how this new version is handled by the body to an existing medication, to see if they work in a similar way after several doses.
SchizophreniaPortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Open-Label Study of Pralsetinib versus Standard Of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer
This study is looking at a new drug called Pralsetinib for advanced lung cancer where a specific genetic change (RET fusion) is present. It compares Pralsetinib to standard treatments to see if it works better or has fewer side effects for people who haven't had treatment for this type of cancer before.
RET fusion−positivemetastatic Non-Small Cell Lung CancerPortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
This study looks at a new medicine called Evolocumab to see if it can lower the chance of serious heart problems like heart attacks or strokes in people at high risk who haven't had them before. It compares Evolocumab to a dummy medicine.
Adults at high risk of cardiovascular events without prior MI or stroke.Portugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM
This study is testing a new medicine, Alnuctamab, for people in the UK with multiple myeloma whose cancer has come back or isn't responding to other treatments. Researchers want to see if Alnuctamab works better and is safer than current treatments, aiming to stop the cancer from growing for longer.
Relapsed and/or Refractory Multiple MyelomaPortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(21177) A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease
This study is looking into a new medication called Finerenone for people with long-term kidney disease that isn't caused by diabetes. It aims to see if the drug can slow down kidney disease progression and if it's safe to use, compared to a dummy pill.
Non-diabetic chronic kidney diseasePortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
"A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS"
This study looks at the long-term safety of a medicine called Cendakimab (also known as CC-93538) for adults with a condition called Eosinophilic Esophagitis. It checks for side effects over a long period to make sure the treatment is safe for people to use.
Eosinophilic esophagitisPortugal - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 study to assess the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for the treatment of fibrodysplasia ossificans progressiva in male and female paediatric and adult participants.
This study is testing a new medicine, fidrisertib, for children and adults with Fibrodysplasia Ossificans Progressiva (FOP). We want to see if it can slow down the new bone growth and reduce flare-ups, and if it's safe to use. Some participants will receive a dummy pill (placebo).
Fibrodysplasia Ossificans ProgressivaPortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis.
This study is testing a new medicine, amlitelimab, for moderate-to-severe eczema in people aged 12 and over. It compares amlitelimab to a dummy medicine (placebo) to see if it improves eczema symptoms like itching and skin clearing.
Dermatitis atopicPortugal - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)
This study looks at new treatments for head and neck cancer that has come back or spread after previous therapies. It compares a new drug, Lenvatinib, alone or with Pembrolizumab, against standard chemotherapy. We want to see if these new approaches help people live longer and improve their health.
Recurrent or metastatic squamous cell carcinoma of the head and neckPortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
This study is looking at a medicine called ozanimod for people with Crohn's disease that is moderate to severe. It wants to see how well the medicine helps reduce their symptoms and improve their gut health over a long period. Researchers will also check how it affects COVID-19 antibody levels.
Moderately to Severely Active Crohn's DiseasePortugal - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase IIb, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Subjects with Cystic Fibrosis Aged 18 Years or Older (CHOICES)
This study is looking at new medications, Dirocaftor, Posenacaftor, and Nesolicaftor, for adults with Cystic Fibrosis. We want to see how well they improve breathing and if they are safe, comparing them to a dummy treatment.
Cystic FibrosisPortugal - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Bioequivalence of Vortioxetine 20 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions
This study is testing a new version of a depression medicine called vortioxetine. We want to see if it works the same way in the body as the original medicine. Healthy volunteers will take a single dose under fasting conditions to help us understand this.
No medical conditionPortugal - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR
This study is looking at a medicine called Secukinumab for people with two conditions: polymyalgia rheumatica (PMR) or giant cell arteritis (GCA). It aims to understand how the medicine works in the body and if it's safe at an early stage.
Polymyalgia rheumatica (PMR)Giant cell arteritis (GCA)Portugal - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate Alzheimer's Disease
This study is testing a new medicine, GV1001, for people with mild to moderate Alzheimer's disease. We want to see if it's safe and if it can help improve memory and thinking over 52 weeks. Half the participants will receive the medicine, and half will receive a dummy injection.
Alzheimer's DiseasePortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
BMS CV027-031, A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
This study is looking at a new medicine called Mavacamten for adults with a heart condition called non-obstructive hypertrophic cardiomyopathy. It aims to see if the medicine can make people feel better and improve their exercise ability over 48 weeks.
Non-obstructive Hypertrophic CardiomyopathyPortugal - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Bioequivalence of Vortioxetine 5 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions.
This study looks at how a new version of the antidepressant medicine called vortioxetine gets into the body. It checks if the new tablet works the same way as the original in healthy volunteers, to make sure it's just as effective.
No medical condition.Portugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
This study is looking at a new way to treat follicular lymphoma, a type of cancer. It compares a drug called Ibrutinib with a standard treatment, Rituximab. The aim is to see if adding Ibrutinib helps people live longer without their cancer getting worse.
Follicular LymphomaPortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)
This study is testing a new inhaled medicine for people with a lung infection called MAC. It wants to see if the new medicine, given with other standard treatments, makes breathing symptoms better and helps clear the infection compared to standard treatments alone.
"Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)"Portugal - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Bioequivalence of Betis®10 mg Film-Coated Tablets versus Clozan 10 mg tablets in Healthy Subjects
This study compares a new medicine called Betis 10mg with an existing medicine called Clozan 10mg. It's for healthy adults and checks if both medicines work the same way in the body. It helps ensure new medicines are just as effective.
No medical condition.Portugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type
This study is testing a new medicine, AVP-786, for people with Alzheimer's disease who experience agitation. It aims to see if the medicine can help reduce agitation and if it's safe to use. Some people will get the medicine, and others will get a dummy pill.
Agitation in Patients With Dementia of the Alzheimer's TypePortugal - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets versus Xeljanz® 10 mg Film-Coated Tablets in Healthy Subjects Under Fed Conditions
This study checked if a new version of the arthritis medicine Tofacitinib works the same way in the body as the original Xeljanz® tablets. It involved healthy people taking the medicine with food to see how it was absorbed.
No medical condition.Portugal - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets versus Xeljanz® 10 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions
This study is testing if a new version of a 10mg "tofacitinib" tablet works the same way in the body as the existing Xeljanz® 10mg tablet. It's for healthy adults and helps ensure new medicines are just as effective.
No medical conditionPortugal